Contraception
Volume 78, Issue 2 , Pages 143-148 , August 2008

Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion

  • Suzan Goodman

      Affiliations

    • University of California, San Francisco, San Francisco, CA 94110, USA
    • Corresponding Author InformationCorresponding author. University of California, San Francisco, San Francisco, CA 94110, USA. Tel.: +1 415 202 4679; fax: +1 415 206 8387.
    • ,
  • Sarah K. Hendlish

      Affiliations

    • Planned Parenthood Golden Gate, San Francisco, CA 94109, USA
    • ,
  • Matthew F. Reeves

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    • Magee-Women's Research Institute, Pittsburgh, PA 15261, USA
    • ,
  • Anne Foster-Rosales

      Affiliations

    • University of California, San Francisco, San Francisco, CA 94110, USA
    • Planned Parenthood Golden Gate, San Francisco, CA 94109, USA

Received 7 December 2007 ,Revised 5 March 2008 ,Accepted 5 March 2008.

References 

  1. Daily EF, Nicholas N, Nelson F, Pakter J. Repeat abortions in New York City: 1970–1972. Fam Plann Perspect. 1973;5:89–93
  2. Fisher W, Singh SS, Shuper PA, et al. Characteristics of women undergoing repeat induced abortion. CMAJ. 2005;72:37–41
  3. Howe B, Kaplan HR, English C. Repeat abortions: blaming the victims. Am J Public Health. 1979;69:1242–1246
  4. Leach J. The repeat abortion patient. Fam Plann Perspect. 1977;9:37–39
  5. Trussell J. Contraceptive efficacy. In:  Hatcher RA,  Trussell J,  Stewart F,  Nelson AL,  Cates W,  Guest F editor. Contraceptive technology. New York: Ardent Media, Inc.; 2004;p. 226;[Chapter 9]
  6. Westfall JM, Kallail KJ. Repeat abortion and use of primary care health services. Fam Plann Perspect. 1995;27:162–165
  7. Jones RK, Singh SS, Finer LB, Frohwirth LF. Repeat abortion in the United States. New York: Guttmacher Institute; 2006;
  8. Goldberg AB, Cardenas LH, Hubbard AE, Darney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception. 2002;66:215–220
  9. Grimes D. Intrauterine devices (IUDs). In:  Hatcher RA,  Trussell J,  Stewart F,  Nelson AL,  Cates WL,  Guest F editor. Contraceptive technology. New York: Ardent Media, Inc.; 2004;p. 497;[Chapter 26]
  10. Lahteenmaki P, Luukkainen T. Return of ovarian function after abortion. Clin Endocrinol. 1978;8:123–132
  11. Gillett PG, Lee NH, Yuzpe AA, Cerskus I. A comparison of the efficacy and acceptability of the copper-7 intrauterine device following immediate or delayed insertion after first-trimester therapeutic abortion. Fert Steril. 1980;34:121–124
  12. Reeves MF, Smith KJ, Creinin MD. Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis. Obstet Gynecol. 2007;109:1286–1294
  13. Stanwood NL, Bradley KA. Young pregnant women's knowledge of modern intrauterine devices. Obstet Gynecol. 2006;108:1417–1422
  14. Forrest JD. U.S. women's perceptions of and attitudes about the IUD. Obstet Gynecol Surv. 1996;51(12 Suppl):S30–S34
  15. Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. Obstet Gynecol. 2002;99:275–280
  16. Goodman S, Hendlish SK, Reeves MF, Benedict C, Pera-Floyd M, Foster-Rosales A. Increasing intrauterine contraception use by reducing barriers to post-abortal and interval insertion. Meet Abstr Contracept. 2006;72:180
  17. Shea K. Personal Communication regarding Planned Parenthood Federation of America Manual of Medical Standards and Guidelines. 15 May, New York; 2005.
  18. Haenszel W, Loveland DB, Sirken MG. Lung cancer mortality as related to residence and smoking histories. J Natl Cancer Inst. 1962;28:947–1001
  19. Berger C, Gold D, Andres D, Gillett P, Kinch R. Repeat abortion: is it a problem?. Fam Plann Perspect. 1984;16:70–77
  20. Millar WJ, Wadhera S, Henshaw SK. Repeat abortions in Canada 1975–1993. Fam Plann Perspect. 1997;29:20–24
  21. Steinhoff P, Smith RG, Palmore JA, Diamond M, Chung CS. Women who obtain repeat abortions: a study based on record linkage. Fam Plann Perspect. 1979;11:30–38
  22. World Health Organization . Medical eligibility criteria for contraceptive use. Geneva, Switzerland: World Health Organization; 2004;
  23. Duenas JL, Albert A, Carrasco F. Intrauterine contraception in nulligravid vs. parous women. Contraception. 1996;53:23–24
  24. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante FR, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561–567
  25. Veldhuis HM, Vos AG, Lagro-Janssen Al. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004;10:82–87
  26. Prager SW, Foster SJ, Darney PD, Drey EA. Risk factors for repeat elective abortion. Am J Obstet Gynecol 2007;197:575, p. e1–e6.
  27. Cohen SA. Repeat abortion, repeat unintended pregnancy, repeated and misguided government policies. Guttmacher Policy Rev. 2007;10:8–12
  28. Faundes A, Telles E, Cristofoletti MDL, Faundes D, Castro S, Hardy E. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception. 1998;58:05–09
  29. Morrison CS, Sekadde-Kigondu C, Miller WC, Weiner DH, Sinei SK. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception. 1999;59:97–106
  30. Bender SS, Geirsson RT. Effectiveness of preabortion counseling on postabortion contraceptive use. Contraception. 2004;69:481–487
  31. Schunmann C, Glasier A. Specialist contraceptive counselling and provision after termination of pregnancy improves uptake of long-acting methods but does not prevent repeat abortion: a randomized trial. Hum Reprod. 2006;21:2296–2303
  32. Garg M, Singh M, Mansour D. Peri-abortion contraceptive care: can we reduce the incidence of repeat abortions?. J Fam Plann Reprod Health Care. 2001;27:77–80

☆ Financial support for this study was provided by FEI Women's Health (now DuraMed), producers of ParagardÒ T380A intrauterine copper contraceptive, who sponsored a Staff Training Pilot at Planned Parenthood Golden Gate (part of the intervention study). Ms. Hendlish is concurrently a research consultant for Berlex, Inc (now Bayer Health Care, Inc.), producers of Mirena® levonorgestrel-releasing intrauterine system.

PII: S0010-7824(08)00108-X

doi: 10.1016/j.contraception.2008.03.003

Contraception
Volume 78, Issue 2 , Pages 143-148 , August 2008

Article Tools

* Image Usage & Resolution